Markman on Oncology

 
 
  • Can BRCA Expression Predict Response to Chemotherapy?   Dr. Maurie Markman reviews a recent paper looking at whether differences in BRCA expression might predict response to IP vs IV chemotherapy in patients with ovarian cancer.
  • Ovarian Guidelines: A Cautionary Tale   To conclude that patients will have superior outcome if treated according to guidelines is not accurate, says Dr. Maurie Markman, commenting on news reports on a study assessing NCCN guidelines.
  • Overcoming Vemurafenib Resistance: Is It That Simple?   Dr. Maurie Markman reports on a modeling study indicating that drug-resistant cells may also display drug dependency, suggesting a novel strategy for overcoming vemurafenib resistance in melanoma.
  • T-DM1 and the Dawn of Precision Medicine   Dr. Maurie Markman sees T-DM1, which combines antitumor activities of trastuzumab and HER2-targeted delivery of a cytotoxic agent, as an example of the precision medicine we can expect in the future.
  • DNA in Pap Tests May Aid in Early Cancer Detection   Dr. Maurie Markman reports on a provocative study in which DNA from endometrial and ovarian tumors was reliably detected in liquid-based Pap tests, suggesting a potential means for early detection.
  • Drugs Can't Kill a Tumor They Can't Reach   Is it 'platinum resistance' or is too little platinum reaching the tumor to cause a response? A study reviewed by Maurie Markman raises striking questions about drug resistance and how to overcome it.
  • Do Patients Understand the Role of Cancer Genetic Testing?   Dr Maurie Markman looks at a recent paper questioning whether patients are sufficiently educated about what it means to test tumors for somatic genetic mutations.
  • USPSTF: No Ovarian Cancer Screening, Except For…   Dr. Maurie Markman reports on the USPSTF recommendation against routine screening for ovarian cancer; women with a family history and genetic risk for the disease may prove to be the exceptions.
  • Turning One Pathway Off Turns Another On: A Cautionary Tale   Therapies that switch off one cancer-promoting signaling pathway may induce another pathway to switch on. Are we prepared to deal with the consequences?
  • KRAS Mutation in CRC and No Cetuximab? Not Necessarily   Dr. Maurie Markman looks at new data suggesting that cetuximab can improve outcomes in patients with colorectal cancer and the specific KRAS mutation G13D.
  • Do Study Abstracts Inform -- or Misinform?   Can you stay current by reading abstracts? Not necessarily. Dr. Maurie Markman comments on a study that shows a lack of concordance between conclusions in peer-reviewed papers and their abstracts.
  • Molecular Therapy for mCRC: Genotype the Primary or the Met?   Dr. Maurie Markman reviews a recent article looking at whether the genotype differs in the primary tumor vs a metastatic site in colorectal cancer -- and how it might influence treatment selection.
  • HPV Test vs Pap Smear: Which Is More Sensitive?   Dr. Maurie Markman reports on a study that assessed the sensitivity of a baseline HPV test in predicting the long-term risk of developing cervical cancer.
  • When an Incurable Cancer Meets a New Genetic Target   Dr. Maurie Markman looks at the broader implications of finding a single genetic mutation in 90% of patients with Waldenström macroglobulinemia.
  • Does BRCA2+ Confer a Survival Advantage in Ovarian Cancer?   Patients with BRCA1 and -2 ovarian cancer are said to have a similar survival advantage to patients without those abnormalities, but Dr. Maurie Markman reports a study that calls this into question.
  • Does Adjuvant Chemotherapy Benefit Elderly Cancer Patients?   Few data are available on the benefit or harm of cancer treatments in elderly patients. Dr. Maurie Markman reports on a study of adjuvant therapy in patients with resected stage 3 colorectal cancer.
  • Using Genetic Tests to Predict Anthracycline Cardiotoxicity   Dr. Maurie Markman looks at data from the Children's Oncology Group suggesting that genetic polymorphisms can predict anthracycline-related cardiomyopathy risk even after low doses of the drug.
  • Kill Infection, Prevent Cancer   Dr. Maurie Markman discusses a study that estimates that 2 million cases of cancer worldwide in 2008 were attributable to infections. Are we doing enough to stop cancer before it starts?
  • Can Genetics Predict Chemo Dose Response in AML?   Genetic profiling is used in patients with acute myeloid leukemia to predict prognosis. Dr. Maurie Markman looks at how it can also be used to predict response to chemotherapy.
  • Can Genetics Predict Quality of Life in Cancer Patients?   Dr. Maurie Markman looks at a recent article suggesting that specific genetic variations might predispose NSCLC patients to -- or protect them from -- disease- and treatment-related toxicities.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.